HedgeCo.Net — Formation Bio, an AI-native pharmaceutical company, announced on October 28 the Formation Bio Drug Development Accelerator Fund, a debut vehicle with $600 million in capital commitments designed to expand its portfolio of clinical-stage medicines.
The fund will finance the acquisition and development of 10 to 15 drug programs over the next three to five years and advance them through key clinical milestones. Formation Bio acquires or in-licenses Phase 1 and Phase 2 programs from pharmaceutical and biotech companies, prioritizing assets with a clear path to clinical proof of concept in diseases with substantial unmet need but limited industry activity.
The structure is a hybrid of a venture fund and an operating company. Formation Bio serves as the fund’s general partner through a wholly owned subsidiary and has committed its own capital alongside LPs. Each funded program sits in a standalone corporate entity, keeping each asset’s economics separate, while relying on Formation Bio’s shared development platform and clinical operations rather than duplicating overhead in each company.
Limited partners include research foundations, institutional endowments, hospitals and philanthropic organizations, according to the company. Formation Bio said the fund exclusively finances programs within its own portfolio.
For life sciences investors, the vehicle is a test of whether an asset-centric, hub-and-spoke model can lower the cost of taking drugs through mid-stage trials. It also shows operating companies tapping fund structures to raise capital from endowments and foundations, a source of patient money that fits the multiyear timelines of clinical development.